The announcement Friday by Merck that it plans to apply for emergency approval of a new experimental oral antiviral treatment for COVID-19 is of particular interest to many physicians who have been hindered or completely blocked from treating their COVID patients off-label with an FDA-approved drug that already is produced by the pharmaceutical giant.
Merck is the producer of ivermectin, which has been shown to be effective in an least 65 controlled studies and 32 randomized controlled trials to fight COVID-19 as a preventative and early- and late-stage treatment.
Gohmert noted Merck itself has discouraged using ivermectin to treat COVID-19.
The Texas lawmaker spotlighted the fact that the cheap and effective ivermectin would directly compete with the new drug it is developing, called molnupiravir.
Dr. Pierre Kory, who has testified of ivermectin's effectiveness against COVID-19 in Senate testimony, said Friday that while Merck says molnupiravir reduces hospitalization and death by 47%, studies show ivermectin's rate is 88%. Is Merck ignoring inexpensive ivermectin?
Gohmert wrote that while ivermectin "Has been used by certain brave doctors around the world to treat COVID-19 for over a year now," it recently became the target of a "Deadly dystopian disinformation campaign," dismissing it as a "Horse dewormer."
In September, more than 8,600 scientists and physicians from around the world signed a declaration condemning public policy makers of "Crimes against humanity" for restricting life-saving treatments such as ivermectin and hydroxychloroquine while quashing debate and scientific inquiry.
It's becoming increasingly difficult to discern fact from fiction, and unfortunately the media has a strong bias. They spin stories to make conservatives look bad and will go to great lengths to avoid reporting on the good that comes from conservative policies. There are a few shining lights in the media landscape-brave conservative outlets that report the truth and offer a different perspective. We must support conservative outlets like this one and ensure that our voices are heard.
No comments:
Post a Comment